Initial experience with sacral neuromodulation for the treatment of lower urinary tract dysfunction in Brazil

ABSTRACT Objectives: We report on the short-term outcomes of sacral neuromodulation (SNM) for treatment of idiopathic lower urinary tract dysfunction in Brazil (procedures performed before 2014). Materials and Methods: Clinical data and surgical outcomes of patients who underwent SNM staged procedures were retrospective evaluated. Urological assessment included a focused medical history and physical examination, measurement of postvoid residual volumes, urodynamics, and bladder diaries. A successful test phase has been defined by improvement of at least 50% of the symptoms, based on bladder diaries. Results: From January 2011 to December 2013, eighteen consecutive patients underwent test phase for SNM due to refractory overactive bladder (15 patients), non-obstructive chronic urinary retention (2 patients), and bladder pain syndrome/interstitial cystitis (1 patient). All patients underwent staged procedures at four outpatient surgical centers. Mean age was 48.3±21.2 (range 10-84 years). There were 16 women and 2 men. Median follow-up was 3 months. Fifteen patients (83.3%) had a successful test phase and underwent implantation of the pulse generator (IPG). Median duration of the test phase was 7 days (range 5–24 days). Mean age was 45.6±18.19 years in responders versus 61.66±34.44 years in non-responders (p=0.242). Mean operative time (test phase) was 99±33.12 min in responders versus 95±35 min for non-responders (p=0.852). No severe complications were reported. Conclusion: SNM is a minimally invasive treatment option for patients with refractory idiopathic lower urinary tract dysfunction. Our initial experience with staged technique showed that tined-lead electrodes yielded a high rate of responders and favorable clinical results in the short-term follow-up.

Disfunção erétil / Erectile dysfunction

Uma grande revolução no tratamento da disfunção erétil, especialmente após o desenvolvimento dos primeiros inibidores da 5-fosfodiesterase (5-PDE), no final dos anos 90, marcou profundamente a história da sexualidade humana, repercutindo sobretudo na população de difícil tratamento (diabetes mellitus, prostatectomizados por câncer e outros casos de disfunção orgânica). Respeitando a estratégia de tratamento de cada urologista, os pacientes devem ser estimulados a experimentar todos os tipos de inibidores da 5-PDE disponíveis. Na falha da farmacoterapia oral, ou quando houver contraindicação para ela, dever-se-á considerar a injeção intracavernosa e, finalmente, implante cirúrgico de prótese peniana.